Peroxisomal single enzyme/protein defect
MONDO:0100257Any peroxisomal disease in which the cause of the disease is a defect in a single enyme or protein.
Also known as: peroxisomal single enzyme/protein defect
36 clinical trials for this condition and its sub-types, 0 tagged with Peroxisomal single enzyme/protein defect itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Peroxisomal single enzyme/protein defect
-
Disorder of peroxisomal transporter 0 trials · 21 incl. sub-types
3 sub-types
- Adrenoleukodystrophy 19 trials · 20 incl. sub-types Sub-types →
- Acyl-CoA binding domain containing protein 5 deficiency 1 trial
- Congenital bile acid synthesis defect 5 0 trials
-
Disorder of glyoxylate metabolism 0 trials · 10 incl. sub-types
1 sub-type
- Alanine glyoxylate aminotransferase deficiency 0 trials · 10 incl. sub-types Sub-types →
-
Disorder of peroxisomal alpha oxidation 0 trials · 4 incl. sub-types
1 sub-type
- Phytanoyl-CoA hydroxylase deficiency 0 trials · 4 incl. sub-types Sub-types →
-
Disorder of peroxisomal beta oxidation 0 trials · 2 incl. sub-types
5 sub-types
-
Disorder of plasmalogens biosynthesis 0 trials · 2 incl. sub-types
5 sub-types
- Rhizomelic chondrodysplasia punctata 2 trials Sub-types →
- Acyl-CoA binding domain containing protein 5 deficiency 1 trial
- Alkylglycerone-phosphate synthase deficiency 0 trials · 1 incl. sub-types Sub-types →
- Glyceronephosphate O-acyltransferase deficiency 0 trials · 1 incl. sub-types Sub-types →
- Fatty acyl-CoA reductase defects 0 trials Sub-types →
-
Disorder of defective peroxisome oxidative status 0 trials · 1 incl. sub-types
3 sub-types
- Mitchell syndrome 1 trial
- Acatalasia 0 trials
- Mulibrey nanism 0 trials
-
1 sub-type
Most studied deeper sub-types
-
Halted gene therapy study raises questions for AMN patients
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase 1/2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused Stopped earlyThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC